

Supplementary Table 2: anti-SARS-CoV-2 monoclonal antibodies

	Antibody	Closest VH	Closest VL	Somatic mutations in V(nt) %		CDRH3 sequence	CDRH3 length
				VH	VL		
Donor CoV 01	TAU-1109	1-18	K3-11	3	2.1	AREEPLYCSGGSCYEFQH	18
	TAU-1110	3-15	L1-47	6.3	3.1	TIDGRGYGYGYGMDV	16
	TAU-1115	3-23	L3-21	2	0.7	AKDLTRDYYDSSGYQTGAFDI	21
	TAU-1145	4-39	L3-21	8.8	7.3	VRPNNEHGGFFFDY	14
	TAU-1148	3-23	K3-15	10.3	6.6	ARAGGSGTYPYYFDW	15
	TAU-1225	3-23	K2-30	5.5	3.3	ARKISTGNQYYYYGMDV	17
	TAU-1236	1-18	K1-39	4.4	5.2	ARVASILGATTRGFDS	16
	TAU-1242	3-11	L1-44	6.5	6.1	ARSTTVFAVRDYYYYMDV	18
	TAU-1245	4-4	L1-44	16.2	10.2	ARESSGVTMPGTSSAFFDP	19
	TAU-2173	4-39	L1-51	4	1.7	ARHRNRTPLDALDF	11
Donor CoV 02	TAU-2189	3-23	L3-25	2	0.7	AKDMDIVVVITGDAFDI	17
	TAU-2230	3-23	L3-25	1.4	2.8	AKDLDIVVVITGDAFDI	17
	TAU-2212	1-2	L3-23	0	0.7	ARGWATYYDILTGYSLFDY	19
	TAU-2218	3-49	K3-20	0	5.6	TGPRPYYDSSGYYPYYFDY	19
	TAU-2220	1-46	L1-44	3.4	2.4	ARTHVAQLWEIWFYDI	16
	TAU-2247	3-9	L3-21	10.1	9.4	AKDRGAALSRLRGMDA	16
	TAU-2255	3-9	L3-21	11.4	11.1	AKDRGAALSRLRGMDA	16
	TAU-2303	3-66	K1-9	2	1.4	ARDLAVYGMMDV	11
	TAU-2310	3-23	L2-14	3.7	1.7	AKGAAPYYYYYYYGMDV	16
	TAU-2312	4-34	L1-36	4.5	4.8	ARPLGYCSGRKCERKEMYY	19
TAU-2381	3-21	L4-60	3.7	1.3	AREGTRYDYVWGSYRPWELDY	21	
TAU-2383	3-66	K1-39	5.8	5.8	ARTRVGSGWDAFDV	14	